FDA Commissioner Clarifies: No "Black Box" Warning Planned for COVID-19 Vaccines

Spread the Message

Read Time:4 Minute, 19 Second

Published: December 16, 2025

WASHINGTON, D.C. — The U.S. Food and Drug Administration (FDA) has no intention of adding its most serious safety warning to COVID-19 vaccines, Commissioner Dr. Marty Makary confirmed on Monday. The statement directly refutes conflicting reports that emerged late last week suggesting the agency was preparing to issue a “black box” warning regarding heart inflammation risks.

The clarification comes amidst a period of heightened scrutiny and internal debate at the federal health agency. On Friday, CNN reported that the FDA was finalizing plans to attach a boxed warning—the agency’s strictest safety alert—to the mRNA vaccines manufactured by Pfizer-BioNTech and Moderna. That report cited sources familiar with the agency’s deliberations and pointed to Dr. Vinay Prasad, the FDA’s Chief Medical and Scientific Officer, as a key architect of the proposed change.

However, in an interview with Bloomberg News on Monday, Dr. Makary dismissed the imminence of such a measure. “The FDA has no plans to put a black box warning on COVID-19 vaccines,” Makary stated, signaling a disconnect between the agency’s leadership and recent internal proposals.

Internal Debates Spill into Public View

The conflicting narratives highlight a rare public rift within the nation’s top health regulator. While Commissioner Makary has moved to quell the rumors, reports indicate that some agency officials have aggressively pushed for the warning.

Sources suggest the push for a stricter warning is linked to a controversial internal memo circulated last month by Dr. Prasad, which alleged that COVID-19 vaccinations may have contributed to the deaths of at least 10 children due to myocarditis. That claim has sparked intense debate within the medical community, with outside experts noting that such findings have not been peer-reviewed or corroborated by broader safety surveillance data.

“Unless the FDA announces it, any claim about what it will do is pure speculation,” said Andrew Nixon, a spokesperson for the Department of Health and Human Services (HHS), in a statement responding to the initial reports.

The Science: Myocarditis Risks in Context

The core of the safety debate revolves around myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the heart’s outer lining). These conditions have been acknowledged as rare side effects of mRNA COVID-19 vaccines since 2021, particularly among adolescent males and young men.

According to FDA data updated in May 2025, the highest estimated incidence of these conditions occurs in males aged 16 to 25.

General Risk: Approximately 8 cases per 1 million doses administered.
High-Risk Group: In males aged 16-25, rates have been estimated at approximately 38 cases per 1 million doses.

Despite these figures, the overwhelming majority of cases are mild and resolve quickly with conservative treatment. “Giving two doses of the vaccine just three months apart was linked to higher rates of side effects,” Dr. Makary noted, suggesting that updated annual dosing schedules may mitigate these risks further compared to the initial primary series protocols.

Expert Reactions and Public Health Implications

The potential for a black box warning—typically reserved for drugs with risks of serious or life-threatening adverse effects, such as opioids or certain acne medications—has alarmed some public health experts who fear it could discourage vaccination among vulnerable populations who still benefit from protection.

Dr. Aaron Kesselheim, a professor of medicine at Harvard Medical School who studies drug regulation, expressed concern over the apparent lack of standard process in these recent deliberations.

“I guess my concern is that in this case, there’s not a process,” Kesselheim told CNN. “There isn’t that same opportunity for discussion and good-faith review of the data on which this decision is being made.”

The confusion also arrives against a backdrop of shifting federal health policies under the current administration. HHS Secretary Robert F. Kennedy Jr. has already implemented significant changes to vaccine access, reportedly limiting government-subsidized access primarily to individuals aged 65 and older and those with underlying health conditions.

Navigating Uncertainty

For healthcare professionals and the public, the “whiplash” of conflicting reports underscores the importance of relying on finalized agency guidance rather than leaks or preliminary discussions.

Dr. Paul Offit, Director of the Vaccine Education Center at Children’s Hospital of Philadelphia, criticized the instability of the messaging. “I think it’s irresponsible and unprofessional,” Offit stated regarding the leaked internal disputes, emphasizing that policy should be driven by rigorous data review, not administrative infighting.

As of Tuesday, the official labeling for Pfizer and Moderna COVID-19 vaccines continues to carry standard warnings about myocarditis and pericarditis but does not include a black box warning. The FDA maintains that the benefits of vaccination in preventing severe disease, hospitalization, and death outweigh the risks for the authorized populations.

Medical Disclaimer

Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.